VNDA Share Price

Open 18.35 Change Price %
High 18.40 1 Day 0.05 0.27
Low 18.15 1 Week 0.67 3.78
Close 18.40 1 Month 2.65 16.83
Volume 650006 1 Year 2.84 18.25
52 Week High 18.75
52 Week Low 12.70
VNDA Important Levels
Resistance 2 18.63
Resistance 1 18.54
Pivot 18.32
Support 1 18.26
Support 2 18.17
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ASTI 0.00 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
ALNY 113.84 51.71%
LOCM 0.09 50.00%
VALV 0.03 50.00%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
ORIG 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

VNDA Technical Analysis 5
As on 20th Sep 2017 VNDA Share Price closed @ 18.40 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.22 & Strong Buy for SHORT-TERM with Stoploss of 16.53 we also expect STOCK to react on Following IMPORTANT LEVELS.
VNDA Target for September
1st Target up-side 18.45
2nd Target up-side 19.32
3rd Target up-side 20.2
1st Target down-side 15.95
2nd Target down-side 15.08
3rd Target down-side 14.2
VNDA Other Details
Segment EQ
Market Capital 96253192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vandapharmaceuticals.com
VNDA Address
VNDA
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
Phone: 202-734-3400
Fax: 202-296-1450
VNDA Latest News
Interactive Technical Analysis Chart Vanda Pharmaceuticals Inc. ( VNDA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vanda Pharmaceuticals Inc.
VNDA Business Profile
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.